Single nucleotide variations target the TP53 3′UTR and the CDS in DLBCL. Acquired somatic mutations (⋆) frequently target both the CDS and the 3′UTR of TP53 with a potential cooperative effect. Expression of TP53 is repressed by some miRNAs, including miR-125b, after binding to target sites located at 3′UTR of the mRNA. In the absence of 3′UTR mutations, wild-type (A) or mutated p53 protein (B) level remain under miRNA repression activity. In the case of mutations disrupting miRNA binding sites that reduce the efficiency of miRNA suppression, wild-type (C) or mutated (D) p53 protein expression is increased with potentially opposite prognostic effects.